Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;45(5):1434-45.
doi: 10.1183/09031936.00174914. Epub 2015 Mar 5.

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Lutz Wollin  1 , Eva Wex  2 , Alexander Pautsch  2 , Gisela Schnapp  2 , Katrin E Hostettler  3 , Susanne Stowasser  4 , Martin Kolb  5
Affiliations
Review

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Lutz Wollin et al. Eur Respir J. 2015 May.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic pathways involved in IPF have not been fully elucidated, IPF is believed to be caused by repetitive alveolar epithelial cell injury and dysregulated repair, in which there is uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts, which excessively deposit extracellular matrix (ECM) proteins in the interstitial space. A number of profibrotic mediators including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor-β are believed to play important roles in the pathogenesis of IPF. Nintedanib is a potent small molecule inhibitor of the receptor tyrosine kinases PDGF receptor, FGF receptor and vascular endothelial growth factor receptor. Data from in vitro studies have shown that nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation, and the secretion of ECM. In addition, nintedanib has shown consistent anti-fibrotic and anti-inflammatory activity in animal models of lung fibrosis. These data provide a strong rationale for the clinical efficacy of nintedanib in patients with IPF, which has recently been demonstrated in phase III clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Figures

FIGURE 1
FIGURE 1
Polypharmacology of nintedanib and the downstream signalling pathways. Nintedanib binds to the intracellular ATP binding pocket of fibroblast growth factor receptors (FGFRs), platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs) resulting in blockage of the autophosphorylation of these receptors and the downstream signalling cascades. Nintedanib might exert additional activity by directly blocking non-receptor kinases like Src and Lck (not illustrated). Nintedanib was shown to inhibit PDGFR phosphorylation and subsequent protein kinase B (Akt) and extracellular signal-regulated kinase (ERK)1/2 phosphorylation in lung tissue from mice. Vascular endothelial growth factor (VEGF) was shown to stimulate angiogenesis via the VEGFR, but also to bind to the PDGFR on fibroblasts, stimulating proliferation. Inhibition by nintedanib ultimately results in reduced proliferation, migration and survival of fibroblasts and, potentially, also to attenuated angiogenesis in the lung. FAK: focal adhesion kinase; FGF: fibroblast growth factor; FRS2: FGFR substrate 2; Grb2: growth factor receptor-bound protein 2; MEK1/2: mitogen-activated protein kinase kinase 1/2; PDGF: platelet-derived growth factor; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; PIP2/3: phosphatidylinositol-2/3-phosphate; PKC: protein kinase C; PLC-γ: phospholipase C-γ; SOS: son of sevenless, a guanine nucleotide exchange factor that acts on the Ras GTPases.
FIGURE 2
FIGURE 2
Crystal structure of nintedanib bound to the active site of the fibroblast growth factor receptor-1 kinase domain. The inhibitor and residues that line the active site are shown in stick representation. Hydrogen bonds are depicted as yellow dots. Key residues are labelled.
FIGURE 3
FIGURE 3
a) Nintedanib inhibits platelet-derived growth factor (PDGF)-BB-stimulated platelet-derived growth factor receptor (PDGFR)-α and β autophosphorylation and proliferation of primary human lung fibroblasts (HLFs). HLFs were incubated with nintedanib at different concentrations and stimulated with PDGF-BB (50 ng·mL−1). PDGFR-α and β phosphorylation was determined by an ELISA specific for the phosphorylated receptors. Proliferation was determined by bromodeoxyuridine incorporation. Concentration-dependent inhibition data are presented as mean±sem (n=3 experiments). Reproduced from [78] with permission from the publisher. b) Nintedanib inhibits basic fibroblast growth factor (FGF) and PDGF-BB-stimulated motility of primary HLF from patients with idiopathic pulmonary fibrosis (IPF-HLF) and without IPF (N-HLF). Human lung fibroblasts were incubated with nintedanib at different concentrations for 30 min before the cells were stimulated with basic FGF (20 ng·mL−1) or PDGF-BB (50 ng·mL−1). Motility of the cells was determined by time lapse microscopy using a Cell-IQ imager (CM Technologies Oy, Tampere, Finland) and manual single cell tracking for 72 h. Mean cell velocity was calculated from three experiments. Inhibition is presented as mean±sem.
FIGURE 4
FIGURE 4
Current understanding of the mode of action of nintedanib in fibrotic lung diseases. The scheme reflects ongoing processes in the pathology of idiopathic pulmonary fibrosis (IPF). As a result of epithelial damage, alveolar epithelial cells undergo apoptosis and epithelial type II cells transform into myofibroblasts (epithelial–mesenchymal transition (EMT)) to provide mesenchymal cells for the initial repair process. Residual lung fibroblasts in the interstitium start to proliferate and migrate to the site of injury. Excessive fibroblast proliferation, migration and transformation to myofibroblasts (fibroblast to myofibroblast transformation (FMT)), and synthesis and deposition of extracellular matrix (ECM) are hallmarks of the fibrotic pathology in IPF. Nintedanib (yellow molecules) interferes with fibroblast/myofibroblast proliferation, FMT and migration. By limiting the number of fibroblasts/myofibroblasts, the synthesis and deposition of ECM are reduced. Nintedanib was found to have no effect on EMT. The effects of nintedanib on fibrocytes and other structural cells of the lung need further exploration. The inhibitory activities of nintedanib are shown in yellow.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vancheri C, Failla M, Crimi N, et al. . Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496–504. - PubMed
    1. Richeldi L, Cottin V, Flaherty KR, et al. . Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 1023–1030. - PubMed
    1. Richeldi L, du Bois RM, Raghu G, et al. . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082. - PubMed
    1. Raghu G, Collard HR, Egan JJ, et al. . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. - PMC - PubMed
    1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304. - PubMed

MeSH terms